查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1620441

2024 - 2032 年医院获得性感染治疗市场机会、成长动力、产业趋势分析与预测

Hospital Acquired Infections Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球医院获得性感染治疗市场估值为126 亿美元，预计2024 年至2032 年复合年增长率为3.2%。相关感染的日益关注所推动。由于多种因素，医院感染的盛行率正在上升，包括住院人数增加、患者住院时间延长以及侵入性医疗设备的使用不断增加。泌尿道感染、肺炎和血液感染等常见感染增加了对有效治疗解决方案的需求。此外，免疫功能低下患者数量的不断增加进一步增加了对这些感染的易感性。

依药物类型划分，市场分为抗菌药物、抗病毒药物、抗真菌药物和其他药物。 2023年，抗菌药物以92亿美元的收入占据市场主导地位。这些药物对于治疗 HAI 至关重要，尤其是在医疗环境中抗生素抗药性细菌不断增加的情况下。抗菌药物对于解决 MRSA 和艰难梭菌等抗药性菌株引起的感染至关重要，这些感染需要有效的治疗干预措施。

就给药途径而言，市场分为静脉注射（IV）、口服、局部和吸入疗法。静脉注射细分市场处于领先地位，到 2023 年将产生 57 亿美元的收入。这对于管理严重感染尤其重要，因为需要采取快速治疗行动来对抗危及生命的情况。静脉注射药物的高效性和立竿见影的效果使其成为治疗危重 HAI 病例的首选。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 126 亿美元
预测值 164 亿美元
复合年增长率 3.2%

2023 年北美市场规模达 47 亿美元，预计 2024 年至 2032 年复合年增长率为 2.5%。北美庞大的医院和医疗机构网络增加了医院感染的风险，因此感染控制措施至关重要。领先製药公司的存在以及持续的研发工作也有助于先进治疗方案的开发和可用性，进一步推动市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 院内感染发生率上升
      • 医疗技术和药物开发的进步
      • 越来越关注病人安全和优质护理
    • 产业陷阱与挑战
      • 缺乏患者意识和诊断
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 报销场景
  • 波特的分析
  • PESTEL分析
  • 管道分析
  • 未来市场趋势
  • 差距分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

  • 主要趋势
  • 抗菌药物
  • 抗病毒药物
  • 抗真菌药物
  • 其他药物种类

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

  • 主要趋势
  • 静脉注射 (IV)
  • 口服
  • 专题
  • 吸入

第 7 章：市场估计与预测：按感染类型，2021 - 2032

  • 主要趋势
  • 手术部位感染
  • 血流感染
  • 泌尿道感染
  • 呼吸器相关性肺炎
  • 其他医院感染

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 9 章：公司简介

  • Abbott
  • AbbVie
  • Allergan
  • Eugia Pharma
  • Bayer
  • DAIICHI SANKYO COMPANY
  • F. Hoffmann-La Roche
  • Glenmark Pharmaceuticals
  • GSK
  • Hikma Pharmaceuticals
  • Melinta Therapeutics
  • Merck & Co
  • Pfizer
  • Sanofi
  • Viatris
简介目录
Product Code: 11913

The Global Hospital Acquired Infections Therapeutics Market was valued at USD 12.6 billion in 2023 and is expected to grow at a CAGR of 3.2% from 2024 to 2032. This growth is largely driven by the rising incidence of healthcare-associated infections, the increasing focus on improved patient care, and active government efforts to control the spread of HAIs. The prevalence of HAIs is climbing due to several factors, including higher hospital admissions, extended patient stays, and the growing use of invasive medical devices. Common infections such as urinary tract infections, pneumonia, and bloodstream infections are contributing to the demand for effective therapeutic solutions. Additionally, the growing population of immunocompromised patients further increases the susceptibility to these infections.

By drug type, the market is segmented into antibacterial, antiviral, antifungal, and other drugs. In 2023, antibacterial drugs dominated the market with a revenue of USD 9.2 billion. These drugs are essential for treating HAIs, especially with the increasing presence of antibiotic-resistant bacteria in healthcare environments. Antibacterial drugs are critical in addressing infections caused by resistant strains like MRSA and Clostridium difficile, which require potent therapeutic interventions.

In terms of administration routes, the market is divided into intravenous (IV), oral, topical, and inhalation therapies. The IV segment led the market, generating USD 5.7 billion in 2023. IV administration is the preferred method in hospital settings, as it ensures the rapid delivery of medications directly into the bloodstream. This is particularly important for managing severe infections, where quick therapeutic action is needed to combat life-threatening conditions. The high efficacy and immediate impact of IV-administered drugs make it the go-to option for managing critical HAI cases.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$12.6 Billion
Forecast Value$16.4 Billion
CAGR3.2%

The North American market accounted for USD 4.7 billion in 2023 and is expected to grow at a CAGR of 2.5% between 2024 and 2032. The demand for HAI therapeutics in the region is driven by the high rate of infections and the presence of an advanced healthcare system. North America's vast network of hospitals and healthcare facilities increases the risk of HAIs, making infection control measures essential. The presence of leading pharmaceutical companies and ongoing research and development efforts also contribute to the development and availability of advanced treatment options, further fueling market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of hospital-acquired infections
      • 3.2.1.2 Advancements in medical technology and drug development
      • 3.2.1.3 Growing focus on patient safety and quality care
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Lack of patient awareness and diagnostics
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Reimbursement scenario
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Pipeline analysis
  • 3.10 Future market trends
  • 3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Antibacterial drugs
  • 5.3 Antiviral drugs
  • 5.4 Antifungal drugs
  • 5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Intravenous (IV)
  • 6.3 Oral
  • 6.4 Topical
  • 6.5 Inhalation

Chapter 7 Market Estimates and Forecast, By Infection Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Surgical site infections
  • 7.3 Bloodstream infections
  • 7.4 Urinary tract infections
  • 7.5 Ventilator-associated pneumonia
  • 7.6 Other hospital infections

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 AbbVie
  • 9.3 Allergan
  • 9.4 Eugia Pharma
  • 9.5 Bayer
  • 9.6 DAIICHI SANKYO COMPANY
  • 9.7 F. Hoffmann-La Roche
  • 9.8 Glenmark Pharmaceuticals
  • 9.9 GSK
  • 9.10 Hikma Pharmaceuticals
  • 9.11 Melinta Therapeutics
  • 9.12 Merck & Co
  • 9.13 Pfizer
  • 9.14 Sanofi
  • 9.15 Viatris